Printer Friendly
The Free Library
14,681,102 articles and books
Member login
User name  
Password 
 
Join us Forgot password?

Abraxis completes AstraZeneca purchase.


Abraxis BioScience Inc. has completed its $334 million acquisition of AstraZeneca plc's U.S.-branded injectable in·ject·a·ble
adj.
Capable of being injected. Used of a drug.

n.
A drug or medicine that can be injected.
 product portfolio of anesthetic and analgesic analgesic (ăn'əljē`zĭk), any of a diverse group of drugs used to relieve pain. Analgesic drugs include the nonsteroidal anti-inflammatory drugs (NSAIDs) such as the salicylates, narcotic drugs such as morphine, and synthetic drugs  drugs, part of a larger partnership between the two drug companies.

Products in this acquisition encompass more than 100 dosage forms and include Diprivan, a leading general anesthetic general anesthetic
n.
An agent that produces loss of sensation and loss of consciousness.
; Naropin, an epidural epidural /epi·du·ral/ (-dur´il) situated upon or outside the dura mater.

ep·i·du·ral
adj.
Located on or over the dura mater.

n.
 agent; and Xylocaine, an anesthetic commonly used by dentists.

Abraxis, based in Los Angeles Los Angeles (lôs ăn`jələs, lŏs, ăn`jəlēz'), city (1990 pop. 3,485,398), seat of Los Angeles co., S Calif.; inc. 1850.  and best known for its Abraxane cancer drug and a line of generic drugs, will now have supply agreements with group purchasing organizations representing the majority of U.S. hospitals, and will assume responsibility for more than 700 individual contracts for this product portfolio.

"This acquisition of these products significantly enhances our market-leading injectable drug portfolio and underscores our ongoing commitment to provide a broad range of both multisource and branded injectables to hospitals, clinics, and ultimately the patients they treat," Chief Executive Patrick Soon-Shiong said in a statement.

Abraxis paid London-based AstraZeneca $259 million at the deal's close and will pay $75 million on the first anniversary of the sale. AstraZeneca will exclusively supply to Abraxis these products for an initial term of five years for the U.S. market. AstraZeneca will continue to administer the distribution of this portfolio of drugs for a limited period of time, the companies said.

AstraZeneca also has granted Abraxis BioScience the fight of first offer to purchase or license its branded anesthetics Anesthetics
Drugs or methodologies used to make a body area free of sensation or pain.

Mentioned in: Appendectomy
 and analgesics Analgesics Definition

Analgesics are medicines that relieve pain.
Purpose

Analgesics are those drugs that mainly provide pain relief.
 portfolio outside of the U.S. should AstraZeneca decide to divest them. In addition, it has agreed that Abraxis will be its preferred partner for consideration of certain proprietary injectable products when patents on these products expire.

In addition, Abraxis and AstraZeneca will launch a five-year U.S. co-promotion of Abraxane on July 1. This partnership will result in a doubling of the sales force and promotional investment in the product, which is approved for the treatment of metatastic breast cancer. In addition, AstraZeneca will share the cost of certain clinical trials that are part of the overall clinical development program.

BY DEBORAH CROWE

Staff Reporter
COPYRIGHT 2006 CBJ, L.P.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2006, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

 Reader Opinion

Title:

Comment:



 

Article Details
Printer friendly Cite/link Email Feedback
Author:Crowe, Deborah
Publication:Los Angeles Business Journal
Geographic Code:4EUUK
Date:Jul 3, 2006
Words:345
Previous Article:Mechanics liens.(Data Bank)
Next Article:Ports announce $2 billion plan for pollution cleanup.
Topics:



Related Articles
AstraZeneca fined $355 million as U.S. cracks down on medicare fraud.(Front Page)(AstraZeneca PLC)
Syngenta, Basel, Switzerland, and Fox Paine, San Francisco, will acquire Advanta BV from AstraZeneca of the UK and Royal Cosun of the Netherlands for...
Adobe helps AstraZeneca streamline global document processes.(Adobe Systems Inc., AstraZeneca PLC)(Brief Article)
FDA approval fails to win American Pharmaceutical support.(American Pharmaceutical Partners Inc.'s stock performance forecast)
Abraxis to open biopharmaceutical campus in Culver City.(Abraxis BioScience Inc. )(Brief article)
Weekly profile.(Company overview)(Brief article)
Abraxis waiting for cancer treatment to cure its Wall Street woes.(Corporate Focus)
Overseas Manufacturing.(West Los Angeles)(Abraxis BioScience Inc. acquires Pfizer Inc.)(Brief article)
Billionaire drug executive gives $35 million to St. John's: big gift to Santa Monica hospital won't be Soon-Shiong's last.(PHILANTHROPY)
Abraxis loses civil suit.(HEALTH CARE & BIOTECH)

Terms of use | Copyright © 2009 Farlex, Inc. | Feedback | For webmasters | Submit articles